Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration for the treatment of congenital adrenal hyperplasia a disease that affects approximately 20,000-30,000 people in the United States. "We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients," said Malcolm Lloyd-Smith, Chief Regulatory Officer of Neurocrine Biosciences.